Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval Rolling submission of the Biologics License Application (BLA) to the FDA has been initiated under the Accelerated Approval pathway RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These data will be presented via four platform presentations and in poster presentations at the 22 nd Annual WORLD Symposium TM taking place in San Diego, CA, February 2-6, 2026. These data will also be available on Sangamo's website on the Presentations page. “These data demonstr
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026GlobeNewswire
- Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten OfferingGlobeNewswire
- Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]Yahoo! Finance
SGMO
Earnings
- 11/6/25 - Miss
SGMO
Sec Filings
- 2/4/26 - Form 8-K
- 2/4/26 - Form 424B5
- 2/3/26 - Form 8-K
- SGMO's page on the SEC website